Impax Asset Management Group plc Has $39.54 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Impax Asset Management Group plc lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 88.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 201,203 shares of the medical research company’s stock after selling 1,591,807 shares during the period. Impax Asset Management Group plc’s holdings in IQVIA were worth $39,538,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. FMR LLC grew its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in IQVIA during the 3rd quarter valued at about $147,683,000. JPMorgan Chase & Co. boosted its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after buying an additional 583,396 shares in the last quarter. Nordea Investment Management AB grew its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after buying an additional 250,458 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Down 1.6 %

Shares of IQV stock opened at $190.94 on Monday. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a market capitalization of $33.62 billion, a PE ratio of 25.46, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. The firm has a 50 day moving average price of $199.57 and a two-hundred day moving average price of $216.25. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on IQV. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. Bank of America cut their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. TD Cowen decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Stifel Nicolaus dropped their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.